Nicholas Laccona - 10 Feb 2023 Form 4 Insider Report for Bellerophon Therapeutics, Inc.

Reporting relationship: FINANCIAL OFFICER, (PFO & PAO)
Issuer ticker: N/A
Reported as of: 10 Feb 2023
Net transaction value: +$76,000
SEC form: 4
Accepted by SEC: 14 Feb 2023, 15:46:13 UTC
Prior SEC filing: 13 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Nicholas Laccona

Filing notes and source

Key filing fact

Nicholas Laccona filed Form 4 for Bellerophon Therapeutics, Inc. on 14 Feb 2023.

Key facts

This page summarizes Nicholas Laccona's Form 4 filing for Bellerophon Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Feb 2023, 15:46.

Change

Previous filing in this sequence was filed on 13 Dec 2022.
Current net transaction value: +$76,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLPH transaction Derivative

Stock Options (right to buy)

Award

Transaction value: $76,000
Shares: +50,000
Change %
Price: $1.52
Shares after: 50,000
Date: 10 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $1.52
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests as to 25% of the underlying shares on February 10, 2024 and the remaining options vest quarterly over a period of 3 years thereafter.